Clinical role of anti-PD-1 immunotherapies in esophageal cancer
Top Cited Papers
Open Access
- 22 March 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 20 (4) , 325-334
Abstract
Anti-PD-1 antibodies in pharmacotherapy for esophageal cancer have caused a paradigm shift in the treatment strategy. New evidence is being generated not only for metastatic or recurrent cases, but also in the perioperative setting, and the role of anti-PD-1 antibodies in the treatment of esophageal cancer will continue to increase. This review summarizes the clinical role of approved anti-PD-1 antibodies, including nivolumab and pembrolizumab, and discusses additional agents supported by phase 3 evidence. We emphasize current standards of care across metastatic and perioperative settings while briefly addressing emerging strategies under clinical evaluation. Anti-PD-1 antibodies containing therapies have become central to ESCC management, improving survival in both metastatic and perioperative settings. Regional phase 3 trials have expanded therapeutic options, although differences in regulatory approval influence global accessibility. Despite these advances, optimal patient selection remains challenging, and predictive biomarkers are urgently needed. Future progress will depend on biomarker development, treatment sequencing, and integration of emerging strategies supported by robust clinical evidence.Keywords
This publication has 35 references indexed in Scilit:
- Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trialeClinicalMedicine, 2025
- LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 studyAnnals of Oncology, 2025
- Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell CarcinomaJAMA Surgery, 2025
- 1532P Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapyAnnals of Oncology, 2023
- O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577Annals of Oncology, 2023
- Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trialAnnals of Oncology, 2022
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialCancer Cell, 2022
- Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II studyESMO Open, 2022
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA, 2021
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusJAMA Oncology, 2019